Immunovant (IMVT) Operating Leases (2020 - 2023)

Immunovant has reported Operating Leases for 4 years, with the latest figure at $47000.0 in Q1 2023.

• For the quarter ending Q1 2023, Operating Leases fell 96.14% year-over-year to $47000.0; the trailing twelve-month figure through Mar 2023 stood at $47000.0 (down 96.14% YoY), and the FY2023 full-year result was $47000.0, down 96.14% from the prior year.
• Operating Leases for Q1 2023 stood at $47000.0, down from $306000.0 in the prior quarter.
• The five-year high for Operating Leases was $4.2 million in Q2 2020, with the low at $47000.0 in Q1 2023.
• Historically, Operating Leases has averaged $1.8 million across 4 years, with a median of $1.6 million in 2021.
• Annual changes were most pronounced in 2022 — Operating Leases tumbled 45.53% — and 2023, when it tumbled 96.14%.
• Immunovant's Operating Leases stood at $2.4 million in 2020, then dropped by 17.56% to $2.0 million in 2021, then slumped by 84.48% to $306000.0 in 2022, then sank by 84.64% to $47000.0 in 2023.
• The last three Operating Leases figures came in at $47000.0 (Q1 2023), $306000.0 (Q4 2022), and $614000.0 (Q3 2022), per Business Quant data.